学术探索
学术期刊
新闻热点
数据分析
智能评审

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques

被引：158
作者：
Stittelaar, KJ
Kuiken, T
de Swart, RL
van Amerongen, G
Vos, HW
Niesters, HGM
van Schalkwijk, P
van der Kwast, T
Wyatt, LS
Moss, B
Osterhaus, ADME
机构：
[1] Erasmus Univ, Inst Virol, NL-3000 DR Rotterdam, Netherlands
[2] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands
[3] Erasmus Univ, Expt Anim Ctr, NL-3000 DR Rotterdam, Netherlands
[4] NIAID, Viral Dis Lab, Bethesda, MD 20892 USA
来源：
VACCINE | 2001年 / 19卷 / 27期
关键词：
modified vaccinia virus Ankara; smallpox; macaques;
D O I：
10.1016/S0264-410X(01)00075-5
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Modified vaccinia virus Ankara (MVA)-based recombinant viruses have been shown to be potent vaccine candidates for several infectious and neoplastic diseases. Since a major application of these live, replication-deficient vectors would be their use in immunocompromised or potentially immunocompromised individuals. a preclinical safety study was carried out. Macaques were inoculated with high doses of MVA (10(9)) via various routes. after immune-suppression by total-body irradiation, anti-thymocyte globulin treatment, or measles virus (MV) infection. No clinical, haematological or pathological abnormalities related to MVA inoculation were observed during a 13-day follow-up period. The presence of MVA genomes was demonstrated by nested PCR during the course of the experiment in ail macaques. but from none of these animals replication competent MVA could be reisolated. These data suggest that MVA can safely be used as a basis for recombinant human vaccines, and that it is also safe for use in immunocompromised individuals. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：3700 / 3709
页数：10
相关论文
共 35 条
[21]   Experimental measles .1. Pathogenesis in the normal and the immunized host [J].
McChesney, MB ;
Miller, CJ ;
Rota, PA ;
Zhu, YD ;
Antipa, L ;
Lerche, NW ;
Ahmed, R ;
Bellini, WJ .
VIROLOGY, 1997, 233 (01) :74-84
[22]   MAPPING OF DELETIONS IN THE GENOME OF THE HIGHLY ATTENUATED VACCINIA VIRUS MVA AND THEIR INFLUENCE ON VIRULENCE [J].
MEYER, H ;
SUTTER, G ;
MAYR, A .
JOURNAL OF GENERAL VIROLOGY, 1991, 72 :1031-1038
[23]  
Neelis KJ, 1997, EXP HEMATOL, V25, P1084
[24]   Vaccination with Rev and Tat against AIDS [J].
Osterhaus, ADME ;
van Baalen, CA ;
Gruters, RA ;
Schutten, M ;
Siebelink, CHJ ;
Hulskotte, EGJ ;
Tijhaar, EJ ;
Randall, RER ;
van Amerongen, G ;
Fleuchaus, A ;
Erfle, V ;
Sutter, G .
VACCINE, 1999, 17 (20-21) :2713-2714
[25]  
Pawelec G, 1999, MECH AGEING DEV, V108, P1
[26]   Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice:: Virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine [J].
Ramírez, JC ;
Gherardi, MM ;
Esteban, M .
JOURNAL OF VIROLOGY, 2000, 74 (02) :923-933
[27]   DISSEMINATED VACCINIA IN A MILITARY RECRUIT WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) DISEASE [J].
REDFIELD, RR ;
WRIGHT, DC ;
JAMES, WD ;
JONES, TS ;
BROWN, C ;
BURKE, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (11) :673-676
[28]   Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara [J].
Schneider, J ;
Gilbert, SC ;
Blanchard, TJ ;
Hanke, T ;
Robson, KJ ;
Hannan, CM ;
Becker, M ;
Sinden, R ;
Smith, GL ;
Hill, AVS .
NATURE MEDICINE, 1998, 4 (04) :397-402
[29]   Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I peptide tetramer [J].
Seth, A ;
Ourmanov, I ;
Kuroda, MJ ;
Schmitz, JE ;
Carroll, MW ;
Wyatt, LS ;
Moss, B ;
Forman, MA ;
Hirsch, VM ;
Letvin, NL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (17) :10112-10116
[30]   Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies [J].
Stittelaar, KJ ;
Wyatt, LS ;
de Swart, RL ;
Vos, HW ;
Groen, J ;
van Amerongen, G ;
van Binnendijk, RS ;
Rozenblatt, S ;
Moss, B ;
Osterhaus, ADME .
JOURNAL OF VIROLOGY, 2000, 74 (09) :4236-4243
1234